200 related articles for article (PubMed ID: 26152812)
1. Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin.
Pawar S; Vavia P
J Drug Target; 2016; 24(1):68-79. PubMed ID: 26152812
[TBL] [Abstract][Full Text] [Related]
2. Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation.
Pawar S; Shevalkar G; Vavia P
J Drug Target; 2016 Sep; 24(8):730-43. PubMed ID: 26878084
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting.
Bragagni M; Mennini N; Ghelardini C; Mura P
J Pharm Pharm Sci; 2012; 15(1):184-96. PubMed ID: 22365096
[TBL] [Abstract][Full Text] [Related]
4. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M
Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236
[TBL] [Abstract][Full Text] [Related]
5. Effect of formulation compositions on niosomal preparations.
Chaw CS; Kim KY
Pharm Dev Technol; 2013; 18(3):667-72. PubMed ID: 22468904
[TBL] [Abstract][Full Text] [Related]
6. Utilization of green formulation technique and efficacy estimation on cell line studies for dual anticancer drug therapy with niosomes.
Khan DH; Bashir S; Correia A; Khan MI; Figueiredo P; Santos HA; Peltonen L
Int J Pharm; 2019 Dec; 572():118764. PubMed ID: 31628977
[TBL] [Abstract][Full Text] [Related]
7. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
Attia IA; El-Gizawy SA; Fouda MA; Donia AM
AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527
[TBL] [Abstract][Full Text] [Related]
8. Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
Mathure D; Madan JR; Gujar KN; Tupsamundre A; Ranpise HA; Dua K
Pharm Nanotechnol; 2018; 6(1):69-78. PubMed ID: 29380709
[TBL] [Abstract][Full Text] [Related]
9. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
10. Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits.
Jain N; Verma A; Jain N
Drug Deliv; 2020 Dec; 27(1):888-899. PubMed ID: 32551978
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of niosomes containing ribavirin for liver targeting.
Hashim F; El-Ridy M; Nasr M; Abdallah Y
Drug Deliv; 2010 Jul; 17(5):282-7. PubMed ID: 20350052
[TBL] [Abstract][Full Text] [Related]
12. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
[TBL] [Abstract][Full Text] [Related]
13. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin.
Ullah S; Shah MR; Shoaib M; Imran M; Elhissi AM; Ahmad F; Ali I; Shah SW
Drug Deliv; 2016 Nov; 23(9):3480-3491. PubMed ID: 27247018
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir.
Akhter S; Kushwaha S; Warsi MH; Anwar M; Ahmad MZ; Ahmad I; Talegaonkar S; Khan ZI; Khar RK; Ahmad FJ
Drug Dev Ind Pharm; 2012 Jan; 38(1):84-92. PubMed ID: 21726136
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of a novel antiacne niosomal gel of rosmarinic acid.
Budhiraja A; Dhingra G
Drug Deliv; 2015; 22(6):723-30. PubMed ID: 24786487
[TBL] [Abstract][Full Text] [Related]
16. Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy.
Tavano L; Muzzalupo R; Mauro L; Pellegrino M; Andò S; Picci N
Langmuir; 2013 Oct; 29(41):12638-46. PubMed ID: 24040748
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
18. Growth Factor-Loaded Nano-niosomal Gel Formulation and Characterization.
Moghassemi S; Hadjizadeh A; Hakamivala A; Omidfar K
AAPS PharmSciTech; 2017 Jan; 18(1):34-41. PubMed ID: 27502406
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of optimized zolmitriptan niosomal emulgel.
Mohamed MI; Abdelbary AA; Kandil SM; Mahmoud TM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1157-1167. PubMed ID: 30919700
[No Abstract] [Full Text] [Related]
20. Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus.
Bendas ER; Abdullah H; El-Komy MH; Kassem MA
Int J Pharm; 2013 Dec; 458(2):287-95. PubMed ID: 24184035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
